Lumos Pharma Inc expected to post a loss of 76 cents a share - Earnings Preview

Lumos Pharma

01/11/2024 14:08

* Lumos Pharma Inc  LUMO.OQ   LUMO.O  is expected to show a
rise
in quarterly revenue when it reports  results on November 5
(estimated) for the period ending September 30 2024
    * The Austin Texas-based  company is expected to report a
2,794.3% increase in revenue to $202.6 thousand from $7 thousand
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Lumos Pharma Inc is for
a loss
of 76 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Lumos
Pharma Inc
is 4.25​, below​ its last closing price of $4.44. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -1.22       -1.24      -0.93     Beat    25
 Mar. 31 0001  -1.18       -1.18      -1.29     Missed  -9.7
 Dec. 31 2023  -1.25       -1.15      -1.17     Missed  -1.7​
 Sep. 30 2023  -1.14       -1.15      -1.04     Beat    9.4
 ​​Jan.        -1.09       -1.10      -1.09     Beat    0.6
 1 0001                                                 
 Mar. 31 2023  -1.11       -1.12      -0.89     Beat    20.8​
 Dec. 31 2022  -0.91       -0.93      -0.99     Missed  -6.3
 Sep. 30 2022  -1.00       -1.01      -0.86     Beat    14.7
 This summary was machine generated November 1 at 14:07 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)